Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals

The recently developed anti‐androgen enzalutamide also known as (MDV3100) has the advantage to prolong by 4.8 months the survival of castration resistant prostate cancer (CRPC) patients. However, the mechanisms behind the potential side effects involving the induction of the prostate cancer (PCa) ne...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Main Authors: Dang, Qiang, Li, Lei, Xie, Hongjun, He, Dalin, Chen, Jiaqi, Song, Wenbing, Chang, Luke S., Chang, Hong-Chiang, Yeh, Shuyuan, Chang, Chawnshang
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2015
Assuntos:
Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528811/
https://ncbi.nlm.nih.gov/pubmed/25817444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2015.02.010
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados